

Patent Owner's Proposed Supplemental Exhibits

Proposed Exhibit No.	Description
2141	Analyst Report: "Spec Pharmaceuticals," <i>Morgan Stanley</i> , March 3, 2014
2142	U.S. Patent No. 8,377,885
2143	Copaxone® 40 mg/mL Promotional Material: produced in <i>In Re Copaxone Consolidated Cases</i> as TEVCOP00449084-115
2144	Teva Internal Document: 2015 MS Mid-Year Tracker, FINAL REPORT APPENDIX – SEPTEMBER 2015
2145	Copaxone® 40 mg/mL Promotional Material: produced in <i>In Re Copaxone Consolidated Cases</i> as TEVCOP00450191-93
2146	Copaxone® 40 mg/mL Promotional Material: produced in <i>In Re Copaxone Consolidated Cases</i> as TEVCOP00451650-52
2147	Analyst Report: "Global Biotechnology and Pharmaceuticals – AAN 2014," <i>Credit Suisse</i> , April 30, 2014.
2148	Analyst Report: "Multiple Sclerosis: It's a Revolution! (vs. Evolution)," <i>Credit Suisse</i> , December 12, 2013.
2149	IMS Data (MS Mkt NSP Sales Ext Units- Sept 2009- Aug 2015; IMS NPA MD_MS SoB Weekly Split_Data Week 10-09-2015; IPS_Total Promotional Spend_2009-2015; NPA MS Mkt – TRx NRx DACON Oct 2009 – Sept 2015)